Literature DB >> 8532719

Hepatocarcinogenesis in transgenic mice.

E P Sandgren1, G Merlino.   

Abstract

Transgenic mouse models of altered hepatic gene expression have provided a new set of tools with which to study the molecular genesis of normal and pathological liver growth. Previously identified carcinogenic genomic changes (such as oncogene activation) can be tested for their transforming potency in liver, and the contribution to liver growth of genetic changes of unknown significance (such as expression of a growth factor) can be directly measured in vivo. Highly novel approaches also have become possible because of the liver's unique regenerative capacity following injury: introduction of cells from another mouse's liver into young AL-uPA mice has resulted in reconstitution of up to 80% of recipient liver by donor cells (Rhim et al., 1994). Use of immunotolerant mice and human donor cells in this approach should allow creation of mice carrying human livers. Finally, by combining transgenic and embryonic stem cell technologies, the latter allowing selective mutation or inactivation of desired genes, we now have the means to begin to answer many of the critical questions regarding mechanisms of liver growth regulation in the intact animal.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 8532719

Source DB:  PubMed          Journal:  Prog Clin Biol Res        ISSN: 0361-7742


  2 in total

1.  A mouse model of hepatocellular carcinoma: ectopic expression of fibroblast growth factor 19 in skeletal muscle of transgenic mice.

Authors:  Katrina Nicholes; Susan Guillet; Elizabeth Tomlinson; Kenneth Hillan; Barbara Wright; Gretchen D Frantz; Thinh A Pham; Lisa Dillard-Telm; Siao Ping Tsai; Jean-Philippe Stephan; Jeremy Stinson; Timothy Stewart; Dorothy M French
Journal:  Am J Pathol       Date:  2002-06       Impact factor: 4.307

2.  Biological Basis of Differential Susceptibility to Hepatocarcinogenesis among Mouse Strains.

Authors:  Robert R Maronpot
Journal:  J Toxicol Pathol       Date:  2009-04-06       Impact factor: 1.628

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.